$BHVN News

Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy

Biohaven Presents Preclinical Data For BHV-1420 At American Society Of Nephrology Kidney Week 2026

Biohaven Could Transform With Troriluzole's FDA Approval, RBC Says

Why Biohaven (BHVN) Is Up 25.0% And What's Next After FDA Review Acceptance

RBC Capital Maintains Sector Perform on Biohaven, Raises Price Target to $22

Biohaven (BHVN) Soars 25% on FDA Drug Review, Price Target Upgrade

Why Biohaven Catapulted 25% — And Why It Might Not Be Done Sprinting

Biohaven Stock Heads for Best Day in 3 Years as FDA Agrees to Review Drug Again

Biohaven’s previously rejected rare disease drug to get fresh FDA review

BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia

Biohaven stock surges 25% on FDA acceptance of drug filing

Biohaven Rebounds With FDA Review Date for Rare Disease Drug

Biohaven partners with Ono in $100m IgG degrader deal

Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven Licenses MoDE IgG Degraders To Ono For Japan, South Korea, Taiwan And ASEAN For Up To $100M Near-Term Payments Including $80M Upfront; BHV-1300 In Phase 3 For Graves' Disease

Biohaven To Present Data On BHV-1530, FGFR3-Directed ADC Using Topoisomerase I Payload, At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics

Has Biohaven (BHVN) Fallen Far Enough to Look Fully Priced?

Xenon Stock Craters on Drug Trial Setback. Its Failure Could Be This Rival’s Gain.

Biohaven’s epilepsy drug hit with FDA clinical hold